Faraday Pharmaceuticals, Inc.

ACTIVE

1616 Eastlake Ave E Ste 560, 华盛顿州金郡, 华盛顿州, United Stateswww.faradaypharma.comHolding1–10 employeesEstablished: 2014-01-01

Clinical Trials

9 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2014

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

71.4%

Phase 2

14.3%

Phase 3

14.3%

Trial Status Distribution

Active, not recruiting

64.3%

Completed

14.3%

Recruiting

14.3%

Terminated

7.1%

Clinical Trials

Trials sponsored by this organization (14)

Evaluation in STEMI Patients Using FDY-5301

Phase 3

Completed

interventional

May 20222,351 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Recruiting

interventional

Mar 20224,600 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Active, not recruiting

interventional

Mar 20224,600 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Active, not recruiting

interventional

Feb 20222,300 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Active, not recruiting

Jan 20224,600 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Active, not recruiting

Dec 20212,300 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Active, not recruiting

interventional

Nov 20214,600 participants

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI)

Phase 1

Active, not recruiting

Nov 20212,300 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations